rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    OTLK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Outlook Therapeutics names Greg DiPasquale as chief commercial officer
      Oct 9Investing.comOTLK
      Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
      Oct 9Yahoo FinanceOTLK
      Outlook Therapeutics applies for permanent J-code for LYTENAVA
      Oct 1Investing.comOTLK
      Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

      Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medic

      Oct 1Yahoo FinanceOTLK
      Outlook Therapeutics at H.C. Wainwright: launch hinges on access
      Sep 12Investing.comOTLK
      Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

      Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. W

      Sep 11Yahoo FinanceOTLK
      Outlook Therapeutics CEO discusses LYTENAVA commercial launch
      Sep 10Investing.comOTLK
      Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

      Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S.

      Sep 10Yahoo FinanceOTLK
      Outlook Therapeutics Announces CFO Transition and Board Change

      Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailOTLK
      Outlook Therapeutics Appoints Kevin Lundquist as CFO

      Outlook Therapeutics (OTLK) said late Thursday it appointed Kevin Lundquist as chief financial offic

      Aug 27Yahoo FinanceOTLK
      Outlook Therapeutics names Kevin Lundquist as CFO
      Aug 27Investing.comOTLK
      Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

      Kevin Lundquist Kevin Lundquist Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LY

      Aug 27Yahoo FinanceOTLK
      Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

      Video webcast now available here ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor “Why Now” on-demand conference. During the segment, Mr. Jahr highlighted why he believes Outlook Therapeuti

      Aug 27Yahoo FinanceOTLK

      This is the newest page. Registered accounts read further back.